1. At a Glance – Lab Coat, Balance Sheet & Mic Drop
Vimta Labs is trading at ₹458, nursing a bruised ego after a ~37% fall in 3 months, yet calmly sitting on a ₹2,042 Cr market cap like a scientist unfazed by stock market tantrums. This is a high-margin, asset-heavy, testing & CRO business with ROCE of 25.2%, ROE of 19.4%, and almost zero debt (D/E 0.02).
Q3 FY26 numbers were… polite but not explosive: Revenue ₹99 Cr (+9.7% YoY), PAT ₹18 Cr (+6.9% YoY), OPM ~35%, EPS ₹3.94. No drama, no disasters, just boring, predictable cash-making laboratories doing what labs do best — testing, validating, and invoicing.
But here’s the twist: Vimta has already sold its clinical diagnostics business to Thyrocare, cleaned up the P&L, launched a biologics CDMO & R&D venture, approved ₹50 Cr capex, got a 1:1 bonus, paid dividends, and still runs debt-light.
So why is the stock sulking? Because markets hate “steady” when they want “spicy.” Question is — do you?
2. Introduction – From Diagnostic Exit to Biologics Entry
Vimta Labs is a 1990-born Hyderabad-based contract research and testing company — basically the nerd who survived every economic cycle while others chased glamour.
Over the last decade, Vimta quietly transformed itself from a mixed-bag diagnostics + testing company into a focused, high-margin, regulatory-heavy CRO & testing platform. The big strategic move? Selling the diagnostics business to Thyrocare in FY25.
That deal wasn’t cosmetic. It removed a lower-margin, operationally noisy segment and allowed Vimta to double down on pharma analytical, preclinical research, food testing, environmental testing, electronics testing, and now biologics CDMO.
FY25 was peak “capital allocation confidence”:
